Supplement Shows Promise in Relieving Brain Fog and Fatigue After Breast Cancer Treatment
“There was a scientific rationale for possible activity, but it had not been studied rigorously,” said Dr. Patricia A. Ganz, describing an oxaloacetate supplement tested on breast cancer survivors.
- A small UCLA clinical trial involving 18 breast cancer survivors tested 500 milligrams of oxaloacetate taken twice daily for eight weeks.
- Participants reported improvements in cognitive impairment, processing speed, executive function, and fatigue.
For roughly 15% to 25% of breast cancer survivors, memory lapses, trouble concentrating, and persistent exhaustion linger years after care ends. Patients and clinicians often refer to these symptoms as chemo brain or brain fog, though chemotherapy is not the sole contributor. The cancer itself, endocrine therapy, inflammation, and hormonal shifts all drive the condition.
Effective treatments remain scarce. To address this clinical gap, researchers at the UCLA Health Jonsson Comprehensive Cancer Center investigated oxaloacetate. The naturally occurring molecule plays an important role in how cells generate energy.
In the Phase II trial published in JCO Oncology Advances, investigators enrolled 18 women diagnosed with early-stage breast cancer one to five years prior. Participants averaged 50 years of age, and nearly 90 percent remained on endocrine therapy during the study. Each person took 500 milligrams of oxaloacetate orally twice a day for eight weeks.
Sixteen participants completed the full eight-week protocol. On measures of cognitive symptoms, the group’s average score shifted from an impaired 29.1 up to a normal 55.5. Standardized tests confirmed parallel gains in processing speed and executive function, alongside marked drops in fatigue and insomnia.
Oxaloacetate was generally well tolerated, though two women withdrew due to gastrointestinal symptoms. Throughout the treatment period, the research team monitored participants for possible side effects.
Because the trial was small and omitted a placebo group, investigators caution that definitive claims cannot yet be made. “Now we have something that seems to be very active and non-toxic and need to take it forward in a placebo controlled trial,” Ganz stated.
To establish causality and rule out placebo effects, the UCLA team prepared a randomized, placebo-controlled Phase II clinical trial. Enrollment was scheduled to begin in late 2026. Researchers are also conducting preclinical mouse studies funded in part by the National Cancer Institute and the Breast Cancer Research Foundation to clarify the biological mechanisms involved.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice.